This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet (London, England), 402(10402), 613-626
Citation
Garvey, W Timothy; Frias, Juan P; Jastreboff, Ania M; le Roux, Carel W; Sattar, Naveed; Aizenberg, Diego; Mao, Huzhang; Zhang, Shuyu; Ahmad, Nadia N; Bunck, Mathijs C; Benabbad, Imane; Zhang, Xiaotian M. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.. Lancet (London, England), 402(10402), 613-626. https://doi.org/10.1016/S0140-6736(23)01200-X